×

Merrimack Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Robert Mulroy, President & CEO, is scheduled to present at the 33rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2015 at 9:30 a.m. (PT) at the Westin St. Francis Hotel in San Francisco.

A live webcast of the presentation can be accessed by visiting the Investors section of Merrimack's website at investors.merrimackpharma.com. A replay of the webcast will be archived on Merrimack's website for two weeks following the presentation.

About Merrimack

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack seeks to gain a deeper understanding of underlying cancer biology through its systems biology-based approach and develop new insights, therapeutics and diagnostics to improve outcomes for cancer patients. Merrimack currently has six oncology therapeutics in clinical development and three additional candidates in late stage preclinical development. Merrimack's lead product candidate, MM-398, recently completed a Phase 3 clinical trial in post-gemcitabine pancreatic cancer. Based on the results of this clinical trial, Merrimack is currently preparing a New Drug Application for MM-398. For more information, please visit Merrimack's website at www.merrimackpharma.com or connect on Twitter at @MerrimackPharma.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.

CONTACT: Investor Contact: Geoffrey Grande, CFA Merrimack 617-441-7602 ggrande@merrimackpharma.com Media Contacts: Dana Robie Merrimack 617-441-7408 drobie@merrimackpharma.com Liz Bryan Spectrum 202-955-6222 lbryan@spectrumscience.com

Source:Merrimack Pharmaceuticals